Rockwell Medical Inc (RMTI)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $27.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rockwell Medical Inc (RMTI) Earnings: Report Dates and Results
Rockwell Medical (RMTI) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Rockwell Medical reported EPS of -$0.59, below the -$0.18 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RMTI has an expected report date of Mar 24, 2027.
RMTI Earnings Call
The latest RMTI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RMTI beat 17, missed 20 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $19.12M, up 20.0% from $15.93M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.59 | -$0.18 | -$0.23 - -$0.13 | -227.78% | Miss | N/A | 2 | 0 up, 1 down | Nov 12, 2026 | $19.12M |
| Jun 30, 2026 | -$0.34 | -$0.17 | -$0.30 - -$0.17 | -100.00% | Miss | N/A | 2 | 1 up, 0 down | Aug 13, 2026 | $17.78M |
| Mar 31, 2026 | -$0.40 | -$0.25 | -$0.40 - -$0.10 | -60.00% | Miss | N/A | 2 | 0 up, 0 down | May 7, 2026 | $17.34M |
| Dec 31, 2025 | -$0.01 | -$0.05 | N/A | +77.78% | Beat | N/A | 2 | 0 up, 0 down | Mar 26, 2026 | $18.35M |
| Sep 30, 2025 | -$0.50 | -$0.45 | -$0.50 - -$0.40 | -11.11% | Miss | -200.0% | 2 | 2 up, 0 down | Nov 12, 2025 | $15.93M |
| Jun 30, 2025 | -$0.50 | -$0.50 | N/A | 0.00% | In line | -600.0% | N/A | 0 up, 0 down | Aug 14, 2025 | $16.07M |
| Mar 31, 2025 | -$0.40 | -$0.50 | N/A | +20.00% | Beat | N/A | N/A | 0 up, 0 down | May 12, 2025 | $18.91M |
| Dec 31, 2024 | -$0.02 | $0.02 | N/A | -200.00% | Miss | N/A | N/A | 0 up, 0 down | Mar 20, 2025 | $24.66M |
| Sep 30, 2024 | $0.50 | $0.10 | $0.10 - $0.10 | +400.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2024 | $28.32M |
| Jun 30, 2024 | $0.10 | -$0.35 | -$0.40 - -$0.30 | +128.57% | Beat | N/A | 2 | 0 up, 0 down | Aug 8, 2024 | $25.83M |
| Mar 31, 2024 | -$0.60 | -$0.40 | -$0.50 - -$0.30 | -50.00% | Miss | N/A | 2 | 0 up, 0 down | May 14, 2024 | $22.68M |
| Dec 31, 2023 | -$0.05 | -$0.07 | -$0.08 - -$0.06 | +28.57% | Beat | N/A | 2 | 0 up, 0 down | Mar 21, 2024 | $22.09M |
| Sep 30, 2023 | -$0.87 | -$0.90 | -$1.20 - -$0.90 | +3.33% | Beat | N/A | 2 | 0 up, 0 down | Nov 14, 2023 | $23.77M |
| Jun 30, 2023 | -$1.69 | -$1.20 | -$1.20 - -$1.20 | -40.83% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2023 | $18.08M |
| Mar 31, 2023 | -$0.10 | -$0.16 | -$0.18 - -$0.15 | +37.50% | Beat | N/A | 2 | 0 up, 0 down | May 15, 2023 | $19.67M |
| Dec 31, 2022 | -$1.40 | -$3.90 | -$3.90 - -$3.90 | +64.10% | Beat | N/A | 2 | 0 up, 0 down | Mar 30, 2023 | $19.31M |
| Sep 30, 2022 | -$4.00 | -$3.70 | -$6.00 - -$3.70 | -8.11% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | $18.69M |
| Jun 30, 2022 | -$5.60 | -$8.10 | N/A | +30.86% | Beat | N/A | N/A | 0 up, 0 down | Aug 15, 2022 | $18.68M |
| Mar 31, 2022 | -$8.40 | -$7.70 | N/A | -9.09% | Miss | N/A | 1 | 0 up, 0 down | Apr 8, 2022 | $16.12M |
| Dec 31, 2021 | -$0.09 | -$0.09 | N/A | -0.01% | Miss | N/A | 1 | 0 up, 0 down | Dec 31, 2021 | $15.33M |
| Sep 30, 2021 | -$8.80 | -$8.25 | -$8.80 - -$7.70 | -6.67% | Miss | N/A | 2 | 1 up, 0 down | Nov 15, 2021 | $15.99M |
| Jun 30, 2021 | -$9.90 | -$8.80 | -$8.80 - -$8.80 | -12.50% | Miss | N/A | 2 | N/A | Aug 16, 2021 | $15.14M |
| Mar 31, 2021 | -$8.80 | -$9.90 | -$9.90 - -$9.90 | +11.11% | Beat | N/A | 1 | N/A | May 17, 2021 | $15.47M |
| Dec 31, 2020 | -$0.99 | -$0.93 | -$0.99 - -$0.88 | -6.45% | Miss | N/A | 2 | N/A | Mar 31, 2021 | $15.16M |
| Sep 30, 2020 | -$11.00 | -$7.70 | -$14.30 - -$7.70 | -42.86% | Miss | N/A | 2 | N/A | Nov 9, 2020 | $15.28M |
| Jun 30, 2020 | -$9.57 | -$15.40 | -$16.50 - -$14.30 | +37.86% | Beat | N/A | 2 | N/A | Aug 10, 2020 | $15.90M |
| Mar 31, 2020 | -$13.20 | -$13.20 | -$15.40 - -$12.10 | 0.00% | In line | N/A | 3 | N/A | May 11, 2020 | $15.86M |
| Dec 31, 2019 | -$1.21 | -$1.36 | -$1.54 - -$1.21 | +11.03% | Beat | N/A | 3 | N/A | Mar 12, 2020 | $15.49M |
| Sep 30, 2019 | -$13.20 | -$17.23 | -$19.80 - -$13.20 | +23.39% | Beat | N/A | 3 | N/A | Nov 11, 2019 | $15.41M |
| Jun 30, 2019 | -$19.80 | -$17.60 | -$20.90 - -$12.10 | -12.50% | Miss | N/A | 4 | N/A | Aug 8, 2019 | $14.85M |
| Mar 31, 2019 | -$1.65 | -$1.98 | -$1.98 - -$1.98 | +16.67% | Beat | N/A | 1 | N/A | May 9, 2019 | $15.56M |
| Dec 31, 2018 | -$1.87 | -$1.43 | -$1.43 - -$1.43 | -30.77% | Miss | N/A | 1 | N/A | Mar 14, 2019 | $16.85M |
| Sep 30, 2018 | -$1.10 | -$1.65 | N/A | +33.33% | Beat | N/A | N/A | N/A | Nov 9, 2018 | $16.67M |
| Jun 30, 2018 | -$2.42 | -$1.43 | -$1.43 - -$1.43 | -69.23% | Miss | N/A | 1 | N/A | Aug 14, 2018 | $14.91M |
| Mar 31, 2018 | -$1.43 | -$1.54 | -$1.54 - -$1.54 | +7.14% | Beat | N/A | 1 | N/A | May 10, 2018 | $14.95M |
| Dec 31, 2017 | -$19.80 | -$13.20 | -$14.30 - -$13.20 | -50.00% | Miss | N/A | 2 | N/A | Mar 15, 2018 | $14.84M |
| Sep 30, 2017 | -$11.00 | -$11.00 | -$12.10 - -$11.00 | 0.00% | In line | N/A | 3 | N/A | Nov 8, 2017 | $14.63M |
| Jun 30, 2017 | -$15.40 | -$11.00 | -$11.00 - -$11.00 | -40.00% | Miss | N/A | 1 | N/A | Aug 9, 2017 | $13.24M |
| Mar 31, 2017 | -$0.99 | -$0.93 | N/A | -6.45% | Miss | N/A | N/A | N/A | May 9, 2017 | $14.59M |
| Dec 31, 2016 | -$11.00 | -$11.55 | N/A | +4.76% | Beat | N/A | N/A | N/A | Mar 15, 2017 | $13.39M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$0.02 the year before. It was -$33.99 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.41 | N/A |
| Dec 31, 2024 | -$0.02 | N/A |
| Dec 31, 2023 | -$2.71 | N/A |
| Dec 31, 2022 | -$19.40 | N/A |
| Dec 31, 2021 | -$27.59 | N/A |
| Dec 31, 2020 | -$34.76 | N/A |
| Dec 31, 2019 | -$35.86 | N/A |
| Dec 31, 2018 | -$6.82 | N/A |
| Dec 31, 2017 | -$47.19 | N/A |
| Dec 31, 2016 | -$33.99 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,700 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,690 | 5 | |
| 2026Q2 | Jun 30, 2026 | 3,862 | 6 | |
| 2026Q1 | Mar 31, 2026 | 2,457 | 5 | |
| 2025Q4 | Dec 31, 2025 | 4,928 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,123 | 7 | |
| 2025Q2 | Jun 30, 2025 | 2,703 | 6 | |
| 2025Q1 | Mar 31, 2025 | 2,440 | 6 | |
| 2024Q3 | Sep 30, 2024 | 3,307 | 6 |
2026Q3 Earnings Call
Opening remarks
Laura Garrett Executive Director of Investor Relations Good morning, everyone, and thank you for joining us for this update on Rockwell Medical. I am thrilled to be joining you today as Rockwell Medical's new Executive Director of Investor Relations. I look forward to working closely with our community and partnering with you moving forward. Joining me on today's conference call are Dr. Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's Chief Financial Officer. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we have no obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's quarterly report on Form 10-Q for the three months ended September 30, 2026, was filed prior to this call. The reconciliation of non-GAAP measures we discuss on today's call can be found in today's press release. Our Form 10-Q and other reports filed with the SEC, along with today's press release and a replay of today's conference call, can be found on Rockwell Medical's website under the Investors section. And with that, I will turn the call over to Rockwell Medical's President and CEO, Dr. Mark Strobeck. Mark?
Mark Strobeck President and CEO Thank you, Laura, and good morning, everyone. Thank you for joining us today for Rockwell Medical's third quarter 2026 Earnings Conference Call and Webcast. We are excited to welcome Laura, who recently joined as our new Executive Director of Investor Relations. Laura brings to Rockwell more than 30 years of experience in investor relations and capital markets, especially within the healthcare sector. Laura now leads our investor relations function and will serve as a key liaison between Rockwell Medical and our shareholders, analysts, prospective investors, and the broader investment community. This morning, our remarks are organized around three key topics. One, the continued execution of our plan for our core hemodialysis business; two, the future impact of our pending acquisition of a global hemodialysis business; and three, the potential opportunity inherent in the new U.S. Health and Human Services Kidney Care National Plan.
Frequently Asked Questions About RMTI
When is Rockwell Medical's next earnings date?
Rockwell Medical's next earnings report is expected for Mar 24, 2027.
Did RMTI beat earnings estimates last quarter?
No. Rockwell Medical reported EPS of -$0.59 for the quarter ended Sep 30, 2026, below the -$0.18 estimate by 227.78%.
What EPS do analysts expect from RMTI next quarter?
The consensus EPS estimate for Rockwell Medical for the quarter ending Dec 31, 2026 is -$0.07 from 4 analysts, with estimates from -$0.07 to -$0.07.
How often does RMTI beat earnings estimates?
Rockwell Medical beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -62.64%.
RMTI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts